Residual Exacerbations With Mepolizumab
Recruiting · NCT04578171 · Observational (researchers observe without assigning treatment) · Lead sponsor: Laval University
View the official record on ClinicalTrials.gov →Interventions studied
Mepolizumab
What this trial is about
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.
Who can take part
Age range
18 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society
- Eligible for mepolizumab treatment
- Able and willing to sign the informed consent form
Exclusion criteria
- Any respiratory disease apart from asthma
- Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome
Where it is running
1 location listed.
- Institut universitaire de cardiologie et de pneumologie de Québec - Québec, Quebec, Canada